var data={"title":"Black widow spider (Latrodectus mactans) antivenom: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Black widow spider (Latrodectus mactans) antivenom: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/5655?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=black-widow-spider-latrodectus-mactans-antivenom-patient-drug-information\" class=\"drug drug_patient\">see &quot;Black widow spider (Latrodectus mactans) antivenom: Patient drug information&quot;</a> and <a href=\"topic.htm?path=black-widow-spider-latrodectus-mactans-antivenom-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Black widow spider (Latrodectus mactans) antivenom: Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F136049\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Antivenin</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F136038\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:0em;display:inline\">The initial dose of antivenin should be administered as soon as possible for prompt relief of symptoms. Delayed antivenin administration may still be effective in treating patients with prolonged or refractory symptoms resulting from black widow spider bites (case report of antivenin administration up to 90 hours after bite; O&rsquo;Malley, 1999). However, delayed administration may decrease effectiveness (Edberg, 2009).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Sensitivity testing:</b> Skin testing may identify allergic individuals, but the lack of an initial reaction does not eliminate the possibility of a hypersensitivity reaction; therefore, always be prepared to treat an unanticipated hypersensitivity reaction. Intradermal skin test or conjunctival test may be performed prior to antivenin administration:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Skin test: Intradermal: Up to 0.02 mL of a 1:10 dilution of normal horse serum in NS; evaluate after 10 minutes against a control test (intradermal injection of NS). <b>Note:</b> A positive reaction is an urticarial wheal surrounded by a zone of erythema.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Conjunctival test: Ophthalmic: Instill 1 drop of a 1:10 dilution of normal horse serum into the conjunctival sac</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <b>Note:</b> Itching of the eye and/or reddening of conjunctiva indicates a positive reaction, usually occurring within 10 minutes.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Desensitization:</b>  <b>Note:</b> In separate vials or syringes, prepare 1:10 and 1:100 dilutions of antivenin in NS.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">SubQ: Inject 0.1 mL, 0.2 mL, and 0.5 mL of the 1:100 dilution at 15- to 30- minute intervals. During this procedure, proceed with the next dose only if a reaction has <b>NOT</b> occurred following the previous dose. Repeat procedure using the 1:10 dilution and then undiluted antivenin. If no reaction has occurred following administration of 0.5 mL of undiluted antivenin, continue the dose at 15-minute intervals until the entire dose has been administered.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">If a reaction occurs, apply a tourniquet proximal to the injection site and administer epinephrine (1 mg/mL) SubQ or IV proximal to the tourniquet or into another extremity. Wait at least 30 minutes; then administer another antivenin injection at the previous dilution which did not evoke a reaction.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Envenomation due to</b> <b><i>Latrodectus mactans</i></b> <b> (black widow spider); envenomation due to other</b> <b><i>Latrodectus</i></b><b> spp (off-label use) (Clark 2001; Isbister 2003):</b> If a positive reaction to a skin or conjunctival test occurs and antivenin therapy is necessary, pretreat the patient with intravenous diphenhydramine and an H<sub>2</sub>-blocker while having a syringe of epinephrine (1 mg/mL) at the bedside: IM, IV: One vial (2.5 mL); a second dose may be needed in some cases; more than 1-2 vials are rarely required</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F136046\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=black-widow-spider-latrodectus-mactans-antivenom-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Black widow spider (Latrodectus mactans) antivenom: Pediatric drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">The initial dose of antivenin should be administered as soon as possible for prompt relief of symptoms. Delayed antivenin administration may still be effective in treating patients with prolonged or refractory symptoms resulting from black widow spider bites (case report of antivenin administration up to 90 hours after bite; O&rsquo;Malley 1999). However, delayed administration may decrease effectiveness (Edberg 2009).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Sensitivity testing:</b> Intradermal skin test or conjunctival test may be performed prior to antivenin administration: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Skin test: Intradermal: Refer to adult dosing.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Conjunctival test: Ophthalmic: Instill 1 drop of a 1:100 dilution of normal horse serum into the conjunctival sac </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">\n      <b>Note:</b> Itching of the eye and/or reddening of conjunctiva indicates a positive reaction, usually occurring within 10 minutes. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Desensitization:</b> Refer to adult dosing.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Envenomation due to</b> <b><i>Latrodectus mactans</i></b> <b> (black widow spider); envenomation due to other</b> <b><i>Latrodectus</i></b><b> spp (off-label use) (Clark 2001; Isbister 2003):</b>  If a positive reaction to a skin or conjunctival test occurs and antivenin therapy is necessary, pretreat the patient with intravenous diphenhydramine and an H<sub>2</sub>-blocker while having a syringe of epinephrine (1 mg/mL) at the bedside:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Children &lt;12 years: IV: One vial (2.5 mL); a second dose may be needed in some cases; more than 1-2 vials are rarely required</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Children &ge;12 years: IM, IV: One vial (2.5 mL); a second dose may be needed in some cases; more than 1-2 vials are rarely required</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F136039\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15673200\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in manufacturer&rsquo;s labeling. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15673201\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in manufacturer&rsquo;s labeling. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F24673690\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Kit, Injection: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 6000 Antivenin units</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F136014\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F136029\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antivenin:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">IM: Administer antivenin in the anterolateral thigh; apply a tourniquet proximal to the injection site if an adverse systemic reaction occurs.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">IV: Administer antivenin over 15 to 30 minutes (Clark, 2001); IV administration is preferred in severe cases, with shock, or in children &lt;12 years of age. There appears to be no clinical difference in efficacy between the IM and IV route of administration (Isbister 2008).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Horse serum for sensitivity testing:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Intradermal: Inject the horse serum test solution into (not under) the skin; evaluate after 10 minutes against a control test (intradermal injection of NS).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Ophthalmic: Instill the horse serum test solution into the conjunctival sac; a positive reaction, if present, will generally occur within 10 minutes</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antivenin for desensitization: SubQ: Administer the antivenin via SubQ injection. Allow 15 to 30 minutes between injections; proceed with the next dose only if a reaction has <b>NOT</b> occurred following the previous dose. If a reaction occurs, apply a tourniquet proximal to the injection site and administer epinephrine (1 mg/mL) SubQ or IV proximal to the tourniquet or into another extremity. Wait at least 30 minutes prior to continuing the desensitization procedure. If no reaction occurs after administration of 0.5 mL of antivenin (undiluted), then may consider administering dose at 15 minute intervals.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F136028\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Envenomation:</b> Treatment of patients with symptoms (eg, cramping, intractable pain, hypertension that are unresponsive to other therapies [eg, benzodiazepines, opioids]) due to <i>Latrodectus mactans</i> (black widow spider) envenomation. The morbidity associated with <i>Latrodectus</i> envenomation is high, but mortality is low; therefore, the antivenin should not be used unless necessary. Clinical trials are being conducted on a purified F(ab)2 antivenom that may be as effective and with a reduced likelihood of adverse effects.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25475104\" class=\"block off-label drugH1Div\"><span class=\"drugH1\">Use: Off-Label</span>\n    <p>Envenomation: Treatment of symptoms (eg, cramping, intractable pain, hypertension) due to Latrodectus spp</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F136020\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;display:inline\">Frequency not defined.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dermatologic: Skin rash (rare; associated with hypersensitivity reaction)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity: Anaphylaxis, hypersensitivity reaction, serum sickness </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neuromuscular &amp; skeletal: Muscle cramps </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F136018\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Allergic reactions: May be less frequent than described in initial studies (Clark, 2001; Offerman, 2011). One retrospective study reviewed 163 cases of black widow spider envenomation; 58 patients received antivenin therapy and only 1 case of anaphylaxis occurred (Clark, 1992). The risk of reaction appears to be greatest with bolus administration of undiluted antivenin (Clark, 2001).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Delayed serum sickness: Delayed serum sickness, albeit uncommon, may occur 1 to 2 weeks following administration, especially when large doses are used (Clark, 2001).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Horse serum hypersensitivity: Carefully review allergies and history of exposure to products containing horse serum. History of atopic sensitivity to horses may increase the risk of immediate sensitivity reactions. Use with caution in patients with asthma, hay fever, or urticaria; fatal anaphylaxis has been reported in patients with a history of asthma. All patients require close monitoring in a setting where resuscitation can be performed.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Elderly patients: Due to an increased risk for complications of envenomation, the administration of antivenin may be the preferred initial therapy in patients &gt;60 years of age. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Thimerosal: Some products may contain thimerosal.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Desensitization: A desensitization protocol is available if sensitivity tests are mildly or questionably positive to reduce risk of immediate severe hypersensitivity reaction. According to the manufacturer, desensitization should be performed when antivenin administration would be lifesaving; however, the risk of anaphylaxis should be weighed against the risks associated with delayed antivenin administration (Rojnuckarin, 2009).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Skin/conjunctival test: A skin or conjunctival test may be performed prior to use; however, the utility of skin and conjunctival tests to accurately identify patients at risk of early (anaphylactic) or late (serum sickness) hypersensitivity reactions to horse-derived antivenins has been questioned (WHO, 2005). Normal horse serum (1:10 dilution) is included for sensitivity testing. The absence of a skin or conjunctival hypersensitivity reaction does not exclude the possibility of anaphylaxis or hypersensitivity following antivenin administration. The false-negative rate for skin testing is 10% with similar agents. Conversely, hypersensitivity is not an absolute contraindication in a significantly envenomated patient.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13298765\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6218053\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=8639&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:0em;display:inline\">There are no known significant interactions.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F136022\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F136033\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Animal reproduction studies have not been conducted. Use during pregnancy (second and third trimester) has been described in case reports; all patients delivered healthy infants (Handel, 1994; Russell, 1979; Sherman, 2000). In general, medications used as antidotes should take into consideration the health and prognosis of the mother; antidotes should be administered to pregnant women if there is a clear indication for use and should not be withheld because of fears of teratogenicity (Bailey, 2003). Treatment of a pregnant patient with antivenom should be considered early in the course of an envenomation and in patients experiencing local, regional, or systemic effects refractory to opioids and/or benzodiazepines (Brown, 2013).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20547315\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">It is not known if antivenin (<i>Latrodectus mactans</i>) is excreted in breast milk. The manufacturer recommends that caution be exercised when administering antivenin (<i>Latrodectus mactans</i>) to nursing women.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F136025\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Vital signs; hypersensitivity reactions; serum sickness reaction (for 2 to 3 weeks following administration); worsening of symptoms due to envenomation</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F136017\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Neutralizes the venom of <i>Latrodectus mactans</i> (black widow spiders), but may also be effective following envenomation by other <i>Latrodectus</i> species (including <i>L. bishopi, L. geometricus, L. hesperus,</i> and <i>L. variolus</i>) (Clark, 2001; Isbister, 2003). </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10180464\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:0em;display:inline\">Onset of action: Within 30 minutes; symptoms of envenomation usually subside after 1-3 hours</p></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Antivenin (<i>Latrodectus mactans</i>) (black widow spider antivenin) [prescribing information]. Whitehouse Station, NJ: Merck &amp; Co; November 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bailey B. Are There Teratogenic Risks Associated With Antidotes Used in the Acute Management of Poisoned Pregnant Women? <i>Birth Defects Res A Clin Mol Teratol</i>. 2003;67(2):133-140.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/black-widow-spider-latrodectus-mactans-antivenom-drug-information/abstract-text/12769509/pubmed\" target=\"_blank\" id=\"12769509\">12769509</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Brown SA, Seifert SA, Rayburn WF. Management of envenomations during pregnancy. <i>Clin Toxicol (Phila)</i>. 2013;51(1):3-15.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/black-widow-spider-latrodectus-mactans-antivenom-drug-information/abstract-text/23298218/pubmed\" target=\"_blank\" id=\"23298218\">23298218</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"11407497\"></a>Clark RF. The Safety and Efficacy of Antivenin <i>Latrodectus mactans</i>.   <i>J Toxicol Clin Toxicol</i>. 2001;39(2):125-127.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/black-widow-spider-latrodectus-mactans-antivenom-drug-information/abstract-text/11407497/pubmed\" target=\"_blank\" id=\"11407497\">11407497</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Clark RF, Wethern-Kestner S, Vance MV, et al. Clinical Presentation and Treatment of Black Widow Spider Envenomation: A Review of 163 Cases.  <i>Ann Emerg Med</i>. 1992;21(7):782-787.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/black-widow-spider-latrodectus-mactans-antivenom-drug-information/abstract-text/1351707/pubmed\" target=\"_blank\" id=\"1351707\">1351707</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dart RC, Bogdan G, Heard K, et al. A randomized, double-blind, placebo-controlled trial of a highly purified equine F(ab)2 antibody black widow spider antivenom.<i> Ann Emerg Med</i>. 2013;61(4):458-467.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/black-widow-spider-latrodectus-mactans-antivenom-drug-information/abstract-text/23380292/pubmed\" target=\"_blank\" id=\"23380292\">23380292</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Edberg AL, Lanphear JR, Riley BD, et al. Toxic Traveler? Latrodectus Species Envenomation in Michigan With Refractory Symptoms After Antivenin Administration. <i>Clin Toxicol (Phila)</i>. 2009;47(4):356-357.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/black-widow-spider-latrodectus-mactans-antivenom-drug-information/abstract-text/19274505/pubmed\" target=\"_blank\" id=\"19274505\">19274505</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Field JM, Hazinski MF, Sayre MR, et al. Part 1: Executive Summary: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. <i>Circulation</i>. 2010;122 (18 suppl 3):640-656.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/black-widow-spider-latrodectus-mactans-antivenom-drug-information/abstract-text/20956217/pubmed\" target=\"_blank\" id=\"20956217\">20956217</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Handel CC, Izquierdo LA,  Curet LB. Black Widow Spider (<i>Latrodectus mactans</i>) Bite During Pregnancy. <i>West J Med</i>. 1994;160(3):261-262.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/black-widow-spider-latrodectus-mactans-antivenom-drug-information/abstract-text/8191768/pubmed\" target=\"_blank\" id=\"8191768\">8191768</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hoyte CO, Cushing TA, Heard KJ. Anaphylaxis to black widow spider antivenom. <i>Am J Emerg Med</i>. 2012;30(5):836.e1-2.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/black-widow-spider-latrodectus-mactans-antivenom-drug-information/abstract-text/21641165/pubmed\" target=\"_blank\" id=\"21641165\">21641165</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Isbister GK, Fan HW. Spider Bite. <i>Lancet</i>. 2011;378(9808):2039-2047.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/black-widow-spider-latrodectus-mactans-antivenom-drug-information/abstract-text/21762981/pubmed\" target=\"_blank\" id=\"21762981\">21762981</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Isbister GK, Brown SG, Miller M, et al. A Randomised Controlled Trial of Intramuscular vs Intravenous Antivenom for latrodectism-the RAVE Study. <i>QJM</i>. 2008;101(7):557-765.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/black-widow-spider-latrodectus-mactans-antivenom-drug-information/abstract-text/18400776/pubmed\" target=\"_blank\" id=\"18400776\">18400776</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"12807312\"></a>Ibister GK, Graudins A, White J, Warrell D. Antivenom treatment in arachnidism. <i>J Toxicol Clin Toxicol</i>. 2003;41(3):291-300.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/black-widow-spider-latrodectus-mactans-antivenom-drug-information/abstract-text/12807312/pubmed\" target=\"_blank\" id=\"12807312\">12807312</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Levine M, Canning J, Chase R, et al. Cardiomyopathy Following <i>Latrodectus</i> Envenomation. <i>West J Emerg Med</i>. 2010;11(5):521-523.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/black-widow-spider-latrodectus-mactans-antivenom-drug-information/abstract-text/21293781/pubmed\" target=\"_blank\" id=\"21293781\">21293781</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Offerman SR, Daubert GP, Clark RF. The Treatment of Black Widow Spider Envenomation With Antivenin <i>Latrodectus Mactans</i>: A Case Series. <i>Permanente J</i>. 2011;15(3):76-81.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    O'Malley GF, Dart RC, Kuffner EF. Successful Treatment of Latrodectism With Antivenin After 90 hours. <i>N Engl J Med</i>. 1999;340(8):657.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/black-widow-spider-latrodectus-mactans-antivenom-drug-information/abstract-text/10049091/pubmed\" target=\"_blank\" id=\"10049091\">10049091</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rojnuckarin P. Antivenom Skin Test: Theory Versus Practice. <i>Acta Tropica</i>. 2009;109(1):86.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Russell FE, Marcus P,  Streng JA. Black Widow Spider Envenomation During Pregnancy: Report of a Case. <i>Toxicon</i>. 1979;17(2):188-189.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/black-widow-spider-latrodectus-mactans-antivenom-drug-information/abstract-text/442109/pubmed\" target=\"_blank\" id=\"442109\">442109</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Saucier JR. Arachnid Envenomation. <i>Emerg Med Clin North Am</i>. 2004;22(2):405-422.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/black-widow-spider-latrodectus-mactans-antivenom-drug-information/abstract-text/15163574/pubmed\" target=\"_blank\" id=\"15163574\">15163574</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Shackleford R, Veillon D, Maxwell N, et al. The black widow spider bite: differential diagnosis, clinical manifestations, and treatment options. <i>J La State Med Soc</i>. 2015;167(2):74-78.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/black-widow-spider-latrodectus-mactans-antivenom-drug-information/abstract-text/25978056/pubmed\" target=\"_blank\" id=\"25978056\">25978056</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sherman RP, Groll JM, Gonzalez DI, et al. Black Widow Spider (<i>Latrodectus mactans</i>) Envenomation in a Term Pregnancy. <i>Curr Surg</i>. 2000;57(4):346-348.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/black-widow-spider-latrodectus-mactans-antivenom-drug-information/abstract-text/11024247/pubmed\" target=\"_blank\" id=\"11024247\">11024247</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    World Health Organization. Guidelines for the Clinical Management of Snake Bites in the South-East Asia Region. 2005. Geneva. Available at  http://www.medbox.org/preview/52724466-84a0-4100-ae90-15f51fcc7b89/doc.pdf</div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 8639 Version 89.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F136049\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F136038\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F136046\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F136039\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F15673200\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F15673201\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F24673690\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F136014\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F136029\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F136028\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Use: Off-Label\" href=\"#F25475104\" class=\"outlineLink\">Use: Off-Label</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F136020\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F136018\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13298765\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F6218053\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F136022\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F136033\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F20547315\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F136025\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F136017\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F10180464\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/8639|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=black-widow-spider-latrodectus-mactans-antivenom-patient-drug-information\" class=\"drug drug_patient\">Black widow spider (Latrodectus mactans) antivenom: Patient drug information</a></li><li><a href=\"topic.htm?path=black-widow-spider-latrodectus-mactans-antivenom-pediatric-drug-information\" class=\"drug drug_pediatric\">Black widow spider (Latrodectus mactans) antivenom: Pediatric drug information</a></li></ul></div></div>","javascript":null}